Carcinoid syndrome: diagnosis and medical management
Arq. bras. endocrinol. metab
; 49(5): 850-860, out. 2005. ilus, tab
Article
en En
| LILACS
| ID: lil-419989
Biblioteca responsable:
BR1.1
ABSTRACT
Gastro-intestinal carcinoids are slow growing tumors arising from enterochromaffin or Kulchitsky cells. Their clinical presentation depends on what combination of bioactive substances is secreted. Midgut carcinoid can present with the carcinoid syndrome in the presence of liver metastases. Its most typical clinical manifestations include cutaneous flushing and diarrhea. A nonspecific biochemical tumor marker for carcinoid tumors is serum chromogranin A and a specific marker for the carcinoid syndrome is the increased urinary excretion of 5-hydroxy indole acetic acid (5-HIAA). Localizing studies in carcinoid tumors/syndrome are transabdominal ultrasonography (US), endoscopy, endoscopic US, videocapsule endoscopy, computerized tomography, magnetic resonance imaging, selective abdominal angiography, 111In-pentetreotide scintigraphy (and intraoperative radionuclide probe), 123I (131I)-metaiodobenzylguanidine (MIBG) scintigraphy, bone scintigraphy and 11C-5-HT positron emission tomography (PET). Therapies for carcinoid tumors/syndrome are surgery, somatostatin analogs, interferon-alpha, radiotherapy, liver dearterialization, liver (chemo, or radio)-embolization, alcohol sclerotherapy of liver metastases, radiofrequency ablation of liver metastases, cryosurgery of liver metastases, occasionally liver transplantation, radiotherapy-coupled somatostatin analogs, 131I-MIBG and occasionally chemotherapy.
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Neoplasias Gastrointestinales
/
Síndrome Carcinoide Maligno
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
Idioma:
En
Revista:
Arq. bras. endocrinol. metab
Asunto de la revista:
ENDOCRINOLOGIA
/
METABOLISMO
Año:
2005
Tipo del documento:
Article
País de afiliación:
Países Bajos
Pais de publicación:
Brasil